Luke A. Gilbert 2026-10-20
A guide specifies the target; the attached Cas9 machinery determines whether expression changes through DNA repair or direct transcriptional regulation. In CRISPR genome editing, a guide RNA supplies sequence complementarity to a genomic target adjacent to a suitable protospacer adjacent motif. The commonly used Cas9 from Streptococcus pyogenes recognizes an NGG motif, where N is any base. Recognition involves both that motif and pairing between the guide and target DNA; an arbitrary complementary sequence is therefore insufficient. In mammalian experiments, a nuclear-localized Cas9 and guide can be delivered by expression constructs or as a preassembled ribonucleoprotein. Multiplexing means supplying several guides, rather than engineering a new DNA-binding protein for every target. The original mammalian demonstration combined programmable targeting with endogenous repair to change genomic sequences.[ref]
Multiplex genome engineering using CRISPR/Cas systems by Le Cong and others. Cong and colleagues, 2013, abstract and results on endogenous mammalian targeting
For a loss-of-function experiment, a cut in an early constitutive exon is repaired by non-homologous end joining and related end-joining pathways. Insertions or deletions can change the reading frame, introduce a premature stop, and trigger nonsense-mediated decay. Neither cleavage nor an insertion/deletion automatically proves a gene knockout: repair can preserve the reading frame, alternative splicing can bypass the exon, and a mammalian cell may retain an intact allele. Targeting a promoter or enhancer can instead alter the amount or cell specificity of expression. Two guides can delete a defined regulatory segment, but the resulting junction and possible larger rearrangements need verification. homology-directed repair with a donor can introduce an expression tag, repair a mutation, or replace a regulatory sequence; its efficiency depends on cell state and competing repair pathways. Changing the genomic coding sequence can change protein activity without changing transcript abundance, so these outcomes should be distinguished.
Expression can also be controlled without cleavage. Catalytically inactive dCas9 retains guide-directed binding. Positioning it at an appropriate regulatory region can obstruct transcription; recruiting a repressive domain such as KRAB strengthens CRISPR interference in mammalian cells. Fusing an activation domain, or recruiting several activators, gives CRISPR activation at an endogenous promoter. These approaches preserve the coding sequence and permit graded or inducible perturbation, although chromatin context and guide position strongly affect performance. Mammalian experiments comparing regulatory fusions established that the same targeting platform can repress or activate transcription.[ref]
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes by Luke A. Gilbert and others. Gilbert and colleagues, 2013, results on dCas9-based repression and activation in eukaryotic cells
The readout should match the proposed mechanism: sequence the target for editing, measure messenger RNA by RT-qPCR, and measure the protein and its biological activity. Use multiple independent guides, a nontargeting guide, delivery-matched controls, and several independently derived clones or a controlled pooled experiment. Rescue with a guide-resistant functional gene supports causality; overexpression rescue alone can have dosage artefacts. Check relevant predicted off-target effects, assess cell viability, and distinguish direct expression changes from selection of surviving cell states. A nuclease perturbation can itself activate a DNA-damage response. Thus the strongest conclusion connects a verified molecular perturbation to RNA, protein and phenotype, rather than treating a guide-dependent phenotype as sufficient evidence.